REFERENCES
1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136-41.
2. Gaubert M, Bardin T, Cohen-Solal A, et al. Hyperuricemia and hypertension, coronary artery disease, kidney disease: from concept to practice. Int J Mol Sci 2020;21:4066.
3. Ali N, Mahmood S, Islam F, et al. Relationship between serum uric acid and hypertension: a cross-sectional study in Bangladeshi adults. Sci Rep 2019;9:9061.
6. Cao Z, Cheng Y, Li S, et al. Mediation of the effect of serum uric acid on the risk of developing hypertension: a population-based cohort study. J Transl Med 2019;17:202.
7. Feig DI. The role of uric acid in the pathogenesis of hypertension in the young. J Clin Hypertens 2012;14:346-52.
8. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 2011;63:102-10.
9. Yokokawa H, Fukuda H, Suzuki A, et al. Association between serum uric acid levels/hyperuricemia and hypertension among 85,286 Japanese workers. J Clin Hypertens (Greenwich) 2016;18:53-9.
10. Fayemi OB, Ajetunmobi WA, Bolaji OB, et al. Relationship between serum uric acid and hypertension among secondary school adolescents in Ekiti State, Nigeria. West Afr J Med 2023;40:997-1002.
11. Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004;66:281-7.
12. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008;300:924-32.
13. Ubhadiya TJ, Dubey N, Sojitra MH, et al. Exploring the effects of elevated serum uric acid levels on hypertension: a scoping review of hyperuricemia. Cureus 2023;15:e43361.
14. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008;27:608-19.
15. Huang Z, Hong Q, Zhang X, et al. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations. Cell Commun Signal 2017;15:3.
16. Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol 2012;121:e71-8.
17. Kimura Y, Tsukui D, Kono H. Uric acid in inflammation and the pathogenesis of atherosclerosis. Int J Mol Sci 2021;22:12394.
18. Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, et al. Uric acid and hypertension: an update with recommendations. Am J Hypertens 2020;33:583-94.
19. Sánchez-Lozada LG, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 2008;23:1179-85.
20. Vermot A, Petit-Härtlein I, Smith SME, Fieschi F. NADPH oxidases (NOX): an overview from discovery, molecular mechanisms to physiology and pathology. Antioxidants 2021;10:890.
21. Kimura Y, Yanagida T, Onda A, Tsukui D, Hosoyamada M, Kono H. Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation. Arterioscler Thromb Vasc Biol 2020;40:570-82.
23. Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J 2006;27:1174-81.
24. Kırça M, Oğuz N, Çetin A, Uzuner F, Yeşilkaya A. Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. J Recept Signal Transduct Res 2017;37:167-73.
25. Li Z, Shen Y, Chen Y, Zhang G, Cheng J, Wang W. High uric acid inhibits cardiomyocyte viability through the ERK/P38 pathway via oxidative stress. Cell Physiol Biochem 2018;45:1156-64.
26. Cordero MD, Williams MR, Ryffel B. AMP-activated protein kinase regulation of the nlrp3 inflammasome during aging. Trends Endocrinol Metab 2018;29:8-17.
27. Crişan TO, Cleophas MCP, Novakovic B, et al. Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway. Proc Natl Acad Sci U S A 2017;114:5485-90.
28. Zhao Y, Qian Y, Sun Z, et al. Role of PI3K in the progression and regression of atherosclerosis. Front Pharmacol 2021;12:632378.
29. Liang WY, Zhu XY, Zhang JW, Feng XR, Wang YC, Liu ML. Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling. Nutr Metab Cardiovasc Dis 2015;25:187-94.
30. Feig DI. Serum uric acid and the risk of hypertension and chronic kidney disease. Curr Opin Rheumatol 2014;26:176-85.
31. Dhanasekar C, Kalaiselvan S, Rasool M. Morin, a bioflavonoid suppresses monosodium urate crystal-induced inflammatory immune response in RAW 264.7 macrophages through the inhibition of inflammatory mediators, intracellular ROS levels and NF-κB activation. PLoS One 2015;10:e0145093.
32. Xiao J, Zhang XL, Fu C, et al. Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the toll-like receptor 4-mediated pathway. Int J Mol Med 2015;35:1347-54.
33. Crouch SH, Botha-Le Roux S, Delles C, Graham LA, Schutte AE. Inflammation and hypertension development: a longitudinal analysis of the African-PREDICT study. Int J Cardiol Hypertens 2020;7:100067.
34. Hong FF, Liang XY, Liu W, et al. Roles of eNOS in atherosclerosis treatment. Inflamm Res 2019;68:429-41.
35. Wei X, Zhang M, Huang S, et al. Hyperuricemia: a key contributor to endothelial dysfunction in cardiovascular diseases. FASEB J 2023;37:e23012.
36. Caldwell RW, Rodriguez PC, Toque HA, Narayanan SP, Caldwell RB. Arginase: a multifaceted enzyme important in health and disease. Physiol Rev 2018;98:641-65.
37. Papežíková I, Pekarová M, Kolářová H, et al. Uric acid modulates vascular endothelial function through the down regulation of nitric oxide production. Free Radic Res 2013;47:82-8.
38. Watanabe T, Ishikawa M, Abe K, et al. Increased lung uric acid deteriorates pulmonary arterial hypertension. J Am Heart Assoc 2021;10:e022712.
39. Kolluru GK, Siamwala JH, Chatterjee S. eNOS phosphorylation in health and disease. Biochimie 2010;92:1186-98.
40. Park JH, Jin YM, Hwang S, Cho DH, Kang DH, Jo I. Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: a mechanism for uric acid-induced cardiovascular disease development. Nitric Oxide 2013;32:36-42.
41. Li P, Zhang L, Zhang M, Zhou C, Lin N. Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: A mechanism for uric acid-induced endothelial dysfunction. Int J Mol Med 2016;37:989-97.
42. Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Henderson GN. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 2008;27:967-78.
43. Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med 2019;33:363-82.
44. Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010;28:1234-42.
45. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-7.
46. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008;26:269-75.
47. Li K, Li K, Yao Q, et al. The potential relationship of coronary artery disease and hyperuricemia: a cardiometabolic risk factor. Heliyon 2023;9:e16097.
48. Yu P, Huang L, Wang Z, Meng X, Yu X. The association of serum uric acid with beta-cell function and insulin resistance in nondiabetic individuals: a cross-sectional study. Diabetes Metab Syndr Obes 2021;14:2673-82.
49. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. Rheumatology 2008;47:713-7.
50. Niu Y, Tang Q, Zhao X, et al. Obesity-induced insulin resistance is mediated by high uric acid in obese children and adolescents. Front Endocrinol 2021;12:773820.
51. Choi YJ, Yoon Y, Lee KY, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J 2014;28:3197-204.
52. Tassone EJ, Cimellaro A, Perticone M, et al. Uric acid impairs insulin signaling by promoting enpp1 binding to insulin receptor in human umbilical vein endothelial cells. Front Endocrinol 2018;9:98.
53. Han T, Lan L, Qu R, et al. Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension. Hypertension 2017;70:703-11.
54. Wan X, Xu C, Lin Y, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol 2016;64:925-32.
55. Takir M, Kostek O, Ozkok A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med 2015;63:924-9.
56. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6.
57. Cristóbal-García M, García-Arroyo FE, Tapia E, et al. Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension. Oxid Med Cell Longev 2015;2015:535686.
58. Sánchez-Lozada LG, Tapia E, Santamaría J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237-47.
59. Romi MM, Arfian N, Tranggono U, Setyaningsih WAW, Sari DCR. Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation. BMC Nephrol 2017;18:326.
60. Ma H, Wang X, Guo X, Li X, Qi L, Li Y. Distinct uric acid trajectories are associated with different risks of incident hypertension in middle-aged adults. Mayo Clin Proc 2019;94:611-9.
61. Zhao H, Lu Z, Lu Y. The potential of probiotics in the amelioration of hyperuricemia. Food Funct 2022;13:2394-414.
62. Robles-Vera I, Toral M, de la Visitación N, et al. Probiotics prevent dysbiosis and the rise in blood pressure in genetic hypertension: role of short-chain fatty acids. Mol Nutr Food Res 2020;64:e1900616.
63. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009;50:1029-34.
64. Sun Q, Zhang T, Manji L, et al. Association between serum uric acid and non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Clin Epidemiol 2023;15:683-93.
65. Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol 2014;29:1926-31.
66. Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension 2020;75:275-84.
67. Mori K, Tanaka M, Hosaka I, et al. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses. Hypertens Res 2023;46:1110-21.
68. Abbasi S, Haleem N, Jadoon S, Farooq A. Association Of non-alcoholic fatty liver disease with serum uric acid. J Ayub Med Coll Abbottabad 2019;31:64-6.
69. Assadi F. Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension. J Nephrol 2014;27:51-6.
70. Beattie CJ, Fulton RL, Higgins P, et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension 2014;64:1102-7.
71. Gill D, Cameron AC, Burgess S, et al. VA Million Veteran Program. Urate, blood pressure, and cardiovascular disease: evidence from mendelian randomization and meta-analysis of clinical trials. Hypertension 2021;77:383-92.
